As promised, we bring you the new and improved FiercePharma

laptop against white background

Many of you saw the new FierceBiotech website launch earlier this week and now I am pleased to bring you the newly redesigned FiercePharma.  Our new website brings all of your Pharma news to a central hub through a more reader-friendly experience.   

Now you can find all of our Pharma related content including stories from our sister sites FiercePharmaManufacturing, FiercePharmaMarketing, FiercePharmaAsia, FierceAnimalHealth, FierceDrugDelivery, and FierceVaccines on one site: www.fiercepharma.com. You will still receive your regular newsletters, so if you subscribe to one of our sister publications the only change you’ll see is a more slimmed-down format.

What’s more exciting than what you’ll see at kickoff are the new features that will enhance our reporting – from social integrations to data visualizations – in the days and weeks to come.   

Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

You’ll also be able to enjoy our content more fully when you're on the go, because our sites will be viewable on desktop, mobile and tablet devices. 

We’re excited to debut the new capabilities the redesign allows and we hope you enjoy our new look. Take a spin through the sites and let me know what you think. 

As always, thank you for reading and for being a part of the FiercePharma community.  – Rebecca Willumson (email | Twitter)

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.